Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...
The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...
Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...
The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025. The FDA has approved Steqeyma ...
A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback